Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Immunotherapy Database @dmeyzie IgorStukalin, @IMDConline collaborators and my mentor @DrDanielHeng@DrChoueiri@montypal@OncoAlert
https://t.co/Li5CwJWKD5
This month’s @EurUrolOncol#SoMe Award is presented to…
Outcomes of Patients with Metastatic RCC Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
https://t.co/HI1T6IOvOf
Congrats to @DrJeffreyGraham, Amishi Y. Shah & coauthors!
#kidneycancer
4/ Looking at all patients with mRCC, incorporating the very favorable category into IMDC criteria, we can identify 4 distinct prognostic groups. @DrBryanChan@JeffreyCGoh1
Outcomes of 1st line combos in inter/poor-risk mRCC from @IMDConline@ChunLGan
🔶Higher ORR, lower PD with IO-VEGF/TKI
🔶Similar oncological outcomes!
🔶Higher irAEs with nivo-ipi but may predict better outcomes!
@OncoAlert#GU21